Edgewise Therapeutics, Inc. (EWTX) Stock Price & How to Invest

Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for rare neuromuscular and serious cardiac conditions. Its lead candidate, sevasemten (formerly EDG-5506), is a skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophy, with the global pivotal GRAND CANYON cohort in Becker due to read out top-line results in the fourth quarter of 2026 and a planned FDA New Drug Application submission in the first half of 2027. A second program, EDG-7500, is a cardiac sarcomere modulator that posted positive 12-week Phase 2 CIRRUS-HCM data in obstructive and nonobstructive hypertrophic cardiomyopathy in mid-2026, with a Phase 3 program targeted to begin in the second half of 2026.

As a pre-commercial company, Edgewise generates no product revenue and runs a steady net loss funded by its balance sheet, reporting roughly $499.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 against a quarterly R&D spend near $42.7 million. The investment picture is a classic clinical-biotech setup: a large market capitalization (around $4.5 billion in mid-2026) built on the expected value of two myosin-modulation programs, a multi-year cash runway, and a share price that tends to move sharply on individual trial readouts. Ownership is a wager on data and eventual regulatory approval rather than on any existing financial results.

As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value depends on binary trial outcomes that can move the stock violently in either direction. A disappointing GRAND CANYON readout or a regulatory setback for sevasemten would remove a large share of the company's expected value. The HCM field is crowded with better-capitalized rivals, so EDG-7500 must show a genuinely differentiated safety and efficacy profile to matter commercially. The company continues to post net losses and will eventually need commercial success or further financing, which could dilute shareholders, and rare-disease trials carry meaningful enrollment, endpoint, and approval uncertainty.

13 analysts publish price targets on EWTX, averaging $49.92 against a $38.43 price as of August 2026, or +29.9%. The published targets run from $30.00 to $66.00, a wide spread, and the ratings split 10 buy, 2 hold, 0 sell. Over the last six months there have been 8 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EWTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Edgewise Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Sevasemten in Becker muscular dystrophy. The lead asset is a first-in-class skeletal myosin inhibitor aimed at slowing muscle degeneration in Becker patients, a population with no approved disease-modifying therapy. The most optimistic published target, $66.00, assumes this works close to its best case.

The case against. As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value depends on binary trial outcomes that can move the stock violently in either direction. The most pessimistic target, $30.00, is roughly what EWTX is worth if this bites instead.

Read the full bull and bear case on EWTX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Edgewise Therapeutics, Inc.'s investor relations page or your broker.

• Product revenue: ~$0 (pre-commercial)
• Cash & marketable securities: ~$499.6M
• Net loss (Q1 2026): ~$49.0M
• Net loss per share (Q1 2026): ~$0.46
• R&D expense (Q1 2026): ~$42.7M
• Market cap (mid-2026): ~$4.5B
• Shares outstanding: ~107.6M

Edgewise generates no product revenue, so traditional valuation multiples do not apply and the stock trades on the expected value of its pipeline. The roughly $499.6 million cash position against a quarterly burn near $50 million supports a runway of several years past the key Becker readout. The multi-billion-dollar market capitalization reflects investor expectations for sevasemten and EDG-7500 rather than any current financial performance.

Other names that sit close to EWTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EWTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EWTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EWTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Edgewise is a cash-rich, pre-revenue clinical biotech whose story lives and dies on late-stage trial data, not earnings.

Whether EWTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EWTX a buy or a sell?, and where the stock could go from here in the EWTX stock forecast.

For income investors, whether EWTX pays a dividend and how the payout looks is covered in does EWTX pay a dividend? And to weigh EWTX against a peer, read the full side-by-side comparisons: EWTX vs BMY and EWTX vs SRPT.